Table 2.
Leukemia-free survival and overall survival of patients with myelodysplastic syndromes (n = 649), categorized by the IPSS-M, IPSS-R, or IPSS.
| Number (%) | Median LFS (months) | 95% CI (months) | C index | Median OS (months) | 95% CI (months) | C index | |
|---|---|---|---|---|---|---|---|
| IPSS-M | 0.738 | 0.730 | |||||
| Very low | 18 (2.8) | 155.7 | 61.1–250.3 | 156.0 | 60.9–251.1 | ||
| Low | 132 (20.3) | 185.5 | 100.3–270.7 | 185.5 | 100.3–270.7 | ||
| Moderate low | 95 (14.6) | 85.2 | 22.6–147.8 | 85.2 | 59.1–111.3 | ||
| Moderate high | 92 (14.2) | 50.6 | 21.0–80.2 | 57.6 | 29.2–86.0 | ||
| High | 121 (18.6) | 25.1 | 17.2–33.0 | 31.1 | 23.6–38.6 | ||
| Very high | 191 (29.4) | 7.8 | 6.6–9.0 | 12.5 | 9.9–15.1 | ||
| IPSS-R | 0.710 | 0.712 | |||||
| Very low | 22 (3.4) | 162.1 | 99.5–224.7 | 162.1 | 99.5–224.7 | ||
| Low | 170 (26.2) | 155.7 | 78.8–232.6 | 156.0 | 84.5–227.5 | ||
| Intermediate | 173 (26.7) | 53.8 | 29.4–78.2 | 57.6 | 35.4–79.8 | ||
| High | 141 (21.7) | 16.0 | 10.9–21.1 | 21.6 | 15.4–27.8 | ||
| Very high | 143 (22.0) | 7.5 | 6.1–8.9 | 8.7 | 6.5–10.9 | ||
| IPSS | 0.681 | 0.679 | |||||
| Low | 106 (16.3) | 162.1 | 79.0–245.2 | 162.1 | 78.6–245.6 | ||
| Intermediate-1 | 302 (46.5) | 68.0 | 36.4–99.6 | 73.3 | 43.9–102.7 | ||
| Intermediate-2 | 167 (57.7) | 11.2 | 8.5–13.9 | 17.2 | 14.0–20.4 | ||
| High | 74 (11.4) | 7.8 | 5.6–10.0 | 10.1 | 7.6–12.6 |
CI confidence interval, IPSS International Prognostic Scoring System, IPSS-M Molecular International Prognostic Scoring System, IPSS-R Revised International Prognostic Scoring System, LFS leukemia-free survival, OS overall survival.